Sumoylation regulates transcription factor transactivation, protein-protein interactions, and appropriate subcellular localization of certain proteins. Previous studies have shown that sumoylation of amyloid precursor protein (APP) is associated with decreased levels of amyloid beta (Aβ) proteins, suggesting that sumoylation may play a role in the pathogenesis of Alzheimer's disease (AD). We investigated the association between polymorphisms of the SUMO genes and the risk of AD. Our study subjects consisted of 144 AD patients and 335 healthy controls without dementia. We focused on tagged single nucleotide polymorphisms (tagSNPs) of the SUMO1 and SUMO2 genes. The tagSNPs were amplified by PCR and sequenced. We used binary logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for the associations between SUMO gene polymorphisms and the risk of AD. We found that rs12472035 polymorphism of SUMO1 was significantly associated with an increased risk of AD in male group (the CT genotype of rs12472035: adjusted OR = 8.737, 95% CI = 2.041-37.41, pvalue = 0.003). In addition, two polymorphisms of SUMO2 were significantly associated with an increased risk of AD in female group (the GA genotype of rs35271045: adjusted OR = 2.879, 95% CI = 1.399-5.924, p-value = 0.004; and the TC genotype of rs9913676: adjusted OR = 2.460, 95% CI = 1.197-5.057, p-value = 0.014). Furthermore, three combinations were associated with an increased risk of AD. Our data suggest that three individual polymorphisms and three combinations may be potential risk factors for AD in Korean population.
Introduction
Dementia is a general term for a decline in memory, cognitive skills, and other mental processes, and is caused by damage to the nerve cells of the brain; the neurons no longer function normally [1] . Worldwide, 35.6 million persons were estimated to have dementia in 2010, and that number is projected to increase to 65.7 million by 2030 and 115.4 million by 2050. Approximately 7.7 million new cases of dementia are diagnosed annually worldwide [2] . The various types of dementia exhibit distinct symptomatic patterns and brain abnormalities, and include Alzheimer's disease (AD), vascular dementia, frontotemporal lobar degeneration (FTLD), dementia with Lewy body disease (DLB), mixed dementia, dementia of Parkinson's disease (PD), and Creutzfeldt-Jakob disease. Of these, AD is the most common form of dementia, and was first identified over 100 years ago. However, the symptoms and causes of, and risk factors for, AD, have been clarified only over the last 30 years [1] . AD has two histopathological hallmarks. These are extracellular aggregations of neuritic plaque, and neurofibrillary tangles (NFTs) in certain brain regions. The NFTs are intracellular accumulations of hyperphosphorylated tau protein [3] . The extracellular neuritic plaques are insoluble deposits of variously sized amyloid beta (Aβ) peptides derived from amyloid precursor protein (APP). Secretases generate Aβ in the endoplasmic reticulum (ER) and Golgi/trans-Golgi Network (TGN). The first step in Aβ peptide generation is cleavage of APP by β-secretase, generating the β-carboxyterminal fragment termed βCTF. This is further cleaved by γ-secretase, generating Aβ peptides [4, 5] .
Sumoylation is a reversible post-translational modification that plays a major role in the regulation of normal protein functions. Sumoylation regulates transcription factor transactivation, proteinprotein interactions, and subcellular localization of certain proteins [6] . Sumoylation has three distinct steps, of which the first is formation of the mature small ubiquitin-related modifier (SUMO) proteins from nascent SUMO proteins via the action of SUMO-specific isopeptidases (sentrin-specific proteases; SENPs). After proteolytic cleavage, the mature SUMO proteins are activated by the SUMO-specific E1-activating enzyme (a heterodimer of AOS1 and UBA2). Next, the SUMO proteins are transferred from the E1-activating enzyme to the E2-conjugating enzyme UBC9. Finally, the SUMO proteins are covalently attached to lysine residues of their target substrates by E3 ligase. Ultimately, the SUMO proteins are removed from their target proteins by SENPs, to become attached to other proteins as another sumoylation cycle commences [7] . The human genome encodes four distinct SUMO proteins (SUMO1, 2, 3, and 4) [8] .
Previous studies found that sumoylation influenced the pathogenesis of AD. Sumoylation of APP with either SUMO1 or SUMO2 was associated with reduced levels of Aβ species, whereas SUMO conjugation-deficient mutations replacing lysine residues (K587R, K595R) were associated with higher levels of Aβ aggregates [9] . Furthermore, enhancement of sumoylation via overexpression of the SUMO-specific E2-conjugating enzyme was associated with decreased levels of the Aβ aggregate [10] . Other studies have shown that overexpression of SUMO3 protein greatly reduced Aβ levels in the HEK293 cell line [11] . In addition, downregulation of another SUMO-related enzyme, SENP3, was significantly associated with AD [12] . A polymorphism (rs761059) of the gene encoding the SUMO-conjugating enzyme Ubc9 was significantly associated with an increased risk of late-onset AD [13] . In addition, previous data suggested that SUMO proteins are closely associated with the risk of AD. So we hypothesized that polymorphisms in the SUMO1 and SUMO2 genes might be associated with such risk, and investigated the associations between such polymorphisms and the risk of AD in Korean patients. To the best of our knowledge, this is the first genetic study to suggest a relationship between SUMO gene polymorphisms and the risk of AD.
Materials and methods

Subjects
The study subjects consisted of 144 AD patients and 335 healthy controls without dementia. The mean age of the AD group (119 females, 25 males) was 79.82 ± 7.02 years and that of the controls (166 females, 169 males) 68.94 ± 6.10 years. The average educational level of the AD group (2.92 ± 3.59 years) was lower than that of the control group (8.29 ± 5.26 years). We define education level by years of education. The frequencies of 10 SUMO genes polymorphisms in both groups are summarized in Table 1 . We recruited AD patients from a dementia clinic of Dankook University Hospital. The cognitively normal control participants were community-dwelling elders who had participated in the Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD) and the Nationwide Dementia Screening and Registration Program (NDSRP) [14] . All subjects underwent standardized clinical interviews and neurological and physical examinations, administered by geriatric psychiatrists with advanced training in neuropsychiatry and dementia research. We used the Korean version of the protocol of the clinical assessment battery established by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K) to diagnose dementia [15] . Dementia was diagnosed using the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), and probable or possible AD was diagnosed using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) [16] . All participants were fully informed about the aims of the study and each participant, or his/her legal guardian, gave written informed consent.
Assessment of neuropsychological functions
Global cognitive function was evaluated via Mini-Mental Status Examination (MMSE) [15, 17] . To assess memory, the word list memory test (WLMT), the word list recall test (WLRT), and the word list recognition test (WLRcT) of the Korean version of the CERAD Neuropsychological Assessment Battery (CERAD-K-N) were administered. Language function was evaluated using the verbal fluency test (VFT). The 15-item modified Boston Naming Test (mBNT) from the CERAD-K-N was also employed [15, 17] . Visuospatial function was evaluated using the constructional praxis test (CPT) of the CERAD-K-N. Frontal function was evaluated using the trail making test A and B of the CERAD-K-N [15, 17] .
Genotyping analysis
First, we selected seven tagSNPs of the SUMO1 gene and two of the SUMO2 gene based on linkage disequilibrium (LD) information and minor allele frequencies (MAFs; cutoff 0.05) in the International HapMap project database (Han Chinese subjects in Beijing, China; Chinese and Japanese subjects in Tokyo, Japan) ( Fig. 1 ). In addition, we included a single intron polymorphism (+ 16446 C N G, lying between exon 1 and exon 2 of the SUMO1 gene; the position is numbered from the translation starting site). We thus genotyped 10 SNPs in total (SUMO1: rs6761234, rs6709162, rs7599810, rs12472035, + 16446 C NG, rs10185956, rs3769817 and rs12693965; SUMO2: rs35271045 and rs9913676) in 144 AD patients and 335 unrelated controls, using PCR/sequencing. The primers used for genotyping were manually designed, and were: rs6761234 forward, 5′-CTTACTCGGGATTGGTTCAT CC-3′ and reverse, 5′-ACTCCTGATTAAGTGCAAATCCC-3′; rs6709162 forward, 5′-CAAAGTGCTCGTACAGAACCC-3′ and reverse, 5′-CTCACCTG ACAACTAGCTGTTC-3′; rs7599810 forward, 5′-GGCCAGTTATGTTGTTGC AG-3′ and reverse, 5′-ACGTCAGTGTGAAAGTGTCC-3′; rs12472035 and +16446 CNG forward, 5′-TGTGCTGAGTAGCCGCTATAG-3′ and reverse, 5′-CTGACTATTACAGCAGCAGGC-3′; rs10185956 forward, 5′-GGAATT GCTGGGTCTAGTATGC-3′ and reverse, 5′-TCAGGAAAGAGCAAGTTGAA ACC-3′; rs3769817 forward, 5′-CCTTCAGTGACACTTCACTTGG-3′ and reverse, 5′-GGACGAACCTGTCTTTGACAG-3′; rs12693965 forward, 5′-GGTGATGGTAACATTAATGGCTGG-3′ and reverse, 5′-CCCACATGCTGT GCAATTTTAATTG-3′; rs35271045 forward, 5′-CTGTGCCCAGCAAGATAC CAT-3′ and reverse, 5′-GACTGGTCTTCCAGCCTTGG-3′; and rs9913676 forward, 5′-GAGACCTGGAGTCTCGCACT-3′ and reverse, 5′-ATCTCGCT GCACTGCTTAGC-3′. All PCR reactions were performed on a C1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA) in a total volume of 25 μL containing 2.5 mM MgCl 2 , 2.5 mM of each dNTP, 100 μM of each primer, 50 ng template DNA, and 1 unit of Taq DNA polymerase. The PCR protocol was as follows: initial denaturation at 94°C for 5 min; 33 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s; and a final extension at 72°C for 3 min. DNA sequencing followed. PCR product directly sequenced using BigDye® Terminator v3.1 cycle sequencing kit on an ABI 3730XL DNA sequencer (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All statistical analyses were performed using SPSS version 23.0 software (SPSS Inc., Chicago, IL, USA). The chi-squared test was used to explore whether genotype distributions in the controls were in Hardy-Weinberg Equilibrium (HWE). Odd ratio (OR) and 95% confidence interval (95% CI) were calculated to estimate the associations between different genotypes in AD patients and healthy controls. Genotype analysis and combination analysis using binary logistic regression adjusted for age, gender and education levels. The LD between the nine tagSNPs was calculated by running pairwise 
Results
The genotype distributions in both AD patients and controls did not deviate from HWE (p N 0.05). The genotyping failure rate was 1.41%. We found no significant differences in genotype frequencies between the AD and control groups when the statistical test was used to analyze data on the seven SUMO1 polymorphisms. We did not identify polymorphisms of the major alleles rs3769817 and rs12693965. However, the CT genotype of the rs12472035 polymorphism was significantly associated with an increased risk of AD in male group (adjusted OR: 8.737, 95% CI: 2.041-37.41), p-value: 0.003). We found that two SUMO2 polymorphisms were significantly associated with the risk of AD in female group (the GA genotype of rs35271045: adjusted OR = 2.879, 95% CI = 1.399-5.924, p-value = 0.004; and the TC genotype of rs9913676: adjusted OR = 2.460, 95% CI = 1.197-5.057, p-value = 0.014). We also investigated the associations between combinations of polymorphisms and the risk of AD. We constructed eight combinations of SUMO gene polymorphisms (combination 1-8: rs6761234-rs6709162-rs12472035, rs6761234-rs7599810-+16446 C N G, rs6761234-rs7599810-rs12472035, rs6761234-+16446 C NGrs12472035, rs6761234-rs12472035-rs10185956, rs7599810-+16446 C NG-rs12472035, rs6761234-rs7599810-+16446 C N G-rs12472035 and rs35271045-rs99113676) for both AD patients and controls. Only eight combinations of SUMO polymorphisms had reference allele in both AD cases and controls. Of these, five combinations (1, 2, 5, 7 and 8) were not significantly with the risk of AD (data not shown). However, combination 3, 4 and 6 were significantly associated with an increased risk of AD (T-T-T type of combination 3: adjusted OR = 5.690, 95% CI = 1.320-24.52, p-value = 0.020; T-G-T type of combination 4: adjusted OR = 5.935, 95% CI = 1.388-25.38, p-value = 0.016; T-G-T type of combination 6: adjusted OR = 5.299, 95% CI = 1.244-22.58, pvalue = 0.024). The data are summarized in Table 2 .
Discussion
Genetic variants are common genome-wide and often indicate connections between certain genes and disease. Of the several types of genetic variants, polymorphisms are apparent in at least 1% of the population. Polymorphisms in the regulatory regions of genes may affect the level of gene expression and protein function. For example, changes in APP sumoylation sites (K587R and K595R) near the β-secretase target region affect the levels of Aβ aggregates [9] .
In recent decades, many studies have identified genetic risk factors for AD. Polymorphisms in amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2) are associated with susceptibility to early-onset familial AD (EOFAD) [18] . In addition, the ε4 variant of apolipoprotein E (ApoE) is closely associated with an increased risk of late-onset Alzheimer's disease (LOAD) [19] . Verghese et al. suggested that ApoE variants were significantly associated not only with AD but also with several other neurological disorders [20] . Recently, large genome-wide association studies (GWAS) have found that variants in 20 genes (9 known genes: CR1, BIN1, CD2AP, EPHA1, CLU1, MS4A6A, PICALM, ABCA7 and CD33; 11 new genes: HLA-DRB5-HLA-DRB1, PTK2B, SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and CASS4) were significantly associated with the risk of AD [21] . Also, several studies have used next-generation sequencing (NGS) to discover new genetic variants in AD patients. In fourteen large families with LOAD, whole-exome sequencing (WES) data indicated that variants in phospholipase 3 (PLD3) were significantly associated with AD. Similarly, replication analysis suggested that PLD3 genetic variants were associated with a much-increased risk of AD in 11,000 subjects of European descent. In addition, it was found that PLD3 overexpression was significantly associated with reduced levels of both intracellular APP and extracellular Aβ, whereas PLD3 knockdown increased Aβ levels [22] . Another WES study on AD found that two rare variants of A-kinase anchor protein 9 (AKAP9) were significantly associated with AD. Replication analysis confirmed that these two rare variants were associated with an increased risk of AD in 2906 subjects [23] . Thus, many potential biomarkers of AD have been discovered with the aid of various techniques. However, the associations between these potential biomarkers and the risk of AD remain unclear.
The SUMO1 gene is located on chromosome 2, and is 32,429 bp in length (exons 1 to 5, including the intronic regions). The International HapMap database identifies nine tagSNPs in the CHB + JPT database (rs10167674, rs6761234, rs13000658, rs7599810, rs12472035, rs10185956, rs3769817, and rs12393965). However, the MAFs of rs10167674 and rs13000658 are 0.0 and 0.006, respectively. The SUMO2 gene is located on chromosome 17, and is 17,398 bp in length (exons 1 to 4, including the intronic regions). The International HapMap database identifies seven tagSNPs in the CHB + JPT database (rs9913676, rs2035252, rs899324, rs899323, rs35271045, rs1471453, and rs7213926). Of these, the MAFs of five (rs2035252, rs899324, rs899323, rs1471453, and rs7213926) are 0.0. In this case-control study, we explored the associations between 10 SUMO gene polymorphisms and the risk of AD in Korean subjects. We found that one polymorphism (rs12472035) of the SUMO1 gene, and two polymorphisms (rs35271045 and rs9913676) of the SUMO2 gene, were significantly associated with an increased risk of AD. In addition, combination analysis revealed that three combinations were significantly associated with a highly increased risk of AD. Our study had two limitations. First, we had relatively few cases and controls. This reduces the statistical power of the observed associations between ten SUMO genes polymorphisms and the risk of AD. Second, we did not consider gene-gene interactions; or gene-environmental interactions such as smoking status, alcohol use status, or disease state. These may affect associations between SUMO gene polymorphisms and the risk of AD.
In conclusions, our data suggest that three SUMO polymorphisms, and combinations of polymorphisms, may be AD potential risk factors. Further work with large numbers of subjects is needed to confirm the relationship between SUMO gene polymorphisms and the risk of AD; environmental factors should also be examined. Also, it is necessary to assess possible associations between polymorphisms in SUMO-related genes and the risk of AD. 
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Bold values means statistically significant (p b 0.05). a Logistic regression adjusted for age, gender and levels of education.
